GME Meeting Planner
Join fellow healthcare professionals for this symposium featuring the world's leading experts who will discuss the latest advances in the pharmacotherapy of anxiety disorders, mood disorders, schizophrenia, and more.
This activity is supported by independent educational grants from Allergan, Merck, Otsuka, Shire, and Sunovion Pharmaceuticals.
Discounted Room Block at JW Marriott Essex House
GME is pleased to offer a discounted room rate for attendees at this meeting. To make your reservations, please follow the link below or call the hotel directly and mention Global Medical Education. We do expect rooms to sell out quickly, so please book your rooms early!
Website Address: https://resweb.passkey.com/go/globalmed
Pharmacotherapy is the mainstay of treatment for psychiatric illnesses. Unfortunately clinicians practice non evidence based pharmacotherapy in the real world. The consequences of undertreatment include poor prognosis, difficulties in interpersonal, occupational and social functioning and suicide. There are several factors contributing to undertreatment. Provider factors include poor professional school education, limited training in interpersonal skills, stigma, inadequate time to evaluate and treat psychiatric illnesses, failure to consider psychotherapeutic approaches, and prescription of inadequate doses of medications for inadequate durations. As an example less than 15% of patients receive guideline concordant care for depression. Another example is the misdiagnosis of patients with bipolar depression as having major depression with needless trials of antidepressants rather than evidence based treatments for bipolar depression. Certain ethnic groups like African Americans, Mexican Americans and Caribbean Blacks are even less likely to receive care. The same is true in patients with bipolar disorder and schizophrenia.
Global Medical Education and Postgraduate Institute of Medicine (PIM ) recently surveyed more than 3,500 CME activity participants on what clinical issues/problems within their scope of practice they would like to see addressed in future educational activities. A significant percentage of respondents reported the following topics as areas of interest: ADHD in children and adults, role of rTMS treatments in psychiatry, neurobiology for psychopharmacology, treating schizophrenia particularly residual negative and cognitive symptoms, safety of psychotropics in pregnancy, mood disorders in children and adolescents, and pharmacotherapy in the following areas: geriatrics, bipolar depression and mixed states, treatment resistant depression particularly for residual cognitive symptoms, eating disorders including binge eating disorder, and sleep disorders particularly hypnotics with new mechanisms of action.
There are several unmet needs in the treatment of bipolar disorder as elicited by clinician survey. A recent survey of more than 200 PCP’s and psychiatrists attending CME meetings in May 2014 found that 19% of PCP’s and 59% of psychiatrists always ask about mania in patients presenting with depression. Only 2%-3% of PCP’s were confident about screening patients for bipolar disorder and only 14% of PCP’s and 44% of psychiatrists were quite confident of recognizing symptoms of bipolar depression. In terms of treating bipolar depression only 2% of PCP’s and 62% of psychiatrists were quite familiar with approved treatment options for bipolar depression. Moreover only 25% of PCP’s knew that antidepressants added to a mood stabilizer was not superior to adding placebo in bipolar depression.
With the availability of several choices of medications even within the same class the clinician has difficulty choosing the best evidence based treatment that takes into consideration not just efficacy but also side effects and costs. Certain symptom domains like cognitive disturbances in major depression and schizophrenia that may be a cause of low rates of remission and increased rates of recurrence can now be targeted with newer antidepressants and potentially innovative adjuncts like alpha7 agonists which may also have utility in patients with dementia. Furthermore studies including the STAR-D, STEP-BD and CATIE trials have demonstrated that even after several levels of treatment a significant proportion of patients do not achieve remission in depression, bipolar disorders and schizophrenia. The use of evidence based augmentation strategies like L-methylfolate and atypical antipsychotics (including newer agents with a more favorable side effect profile) should be used rather than non-evidence based treatments like bupropion, buspirone, and combination of antidepressants. Familiarity with new and innovative approaches including neuromodulatory treatments particularly rTms to manage treatment resistant populations are warranted but based on the evidence and not conjecture. This unfortunately does not occur in the real world with costs to the patients, families and payors. Use of neuromodulatory treatments in dementia, ADHD, substance abuse, and eating disorders will also be discussed. New agents in development that target negative and cognitive disturbances in patients with schizophrenia will also be discussed. This is one of the great unmet needs in the treatment of schizophrenia.
In certain disorders there is concern in the lay media about overdiagnosis ( eg. ADHD) and overtreatment, such as in children and adolescents, pregnant and nursing mothers, and in the elderly particularly with regard to stimulants, antidepressants and antipsychotics. Unfortunately the evidence base is often ignored in the consideration of the judicious use of psychotropics in accurately diagnosed populations which this symposium will address. Controversies and myths surrounding the treatment of these populations will be discussed. New and innovative treatments including use of dopamine-norepinephrine reuptake inhibitors in ADHD will be discussed.
According to the National Center for Sleep Disorders Research at the National Institutes of Health, about 30-40% of adults say they have some symptoms of insomnia within a given year, and about 10-15 percent of adults say they have chronic insomnia. Unfortunately many psychiatric patients have insomnia as a symptom of the psychiatric illness or often as a side effect of the medications. Choosing evidence based treatments with the least risk of dependence and disruptive day time effects particularly on alertness and cognition is key to the management of the psychiatric illness. New and unique mechanisms of action for treating sleep disorders will also be discussed.
There are many unmet needs in the treatment of eating disorders including binge eating disorder a diagnosis new to DSM-5. Non pharmacological therapies including CBT, DBT and IPT have limited ability to produce remission. New and innovative treatments are being studied for the pharmacotherapy of eating disorders that this symposium will address.
Non adherence is a pernicious concern in patients with psychiatric illnesses. Innovative approaches including the use of injectable long acting medications are under-utilized in the US. The symposium will address the evidence base for these treatments in schizophrenia, bipolar disorder and substance abuse.
There are marked differences in the receptor pharmacology of psychotropics leading to differences in efficacy and side effects. The symposium will address our understanding of the neurobiology of psychiatric illnesses and hypothesis of how these medications work including their effects on synaptic function, gene expression and neurotrophic factors.
The symposium will also address the role of non-pharmacological treatments that busy psychopharmacologists can incorporate into their practice that will enhance remission and improve outcomes. The important role of the therapeutic alliance will be emphasized throughout this symposium.
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, registered nurses, psychologists, social workers, and pharmacists who care for patients with psychiatric illnesses.
Stay tuned, more informtion available soon!
Day 1 - Friday, September 8
7:30 - 8:15 AM: Registration and Breakfast
8:15 - 8:30 AM: Opening Remarks
8:30 - 9:30 AM: Keynote Address: "From Receptors to Bedside" - Alan Schatzberg, MD (Stanford University)
9:30 - 10:30 AM: “Pharmacotherapies for Psychiatric Disorders: What Does the Future Hold?" - Roger McIntyre, MD (Univesrity of Toronto)
10:30 - 11:30 AM: “Pharmacotherapy of Schizophrenia” - Oliver Freudenreich, MD (Harvard)
11:30 - 11:45 AM: Coffee Break
11:45 AM - 12:45 PM: Hot Topics (Six clinically relevant and topical issues for 8 minutes each)
12:45-2:00 PM: Lunch
2:00 – 3:00 PM: “Pharmacotherapy of Menopausal and Postpartum Depression” - Samantha Meltzer-Brody, MD (UNC Chapel Hill)
3:00 – 4:00 PM: "Management of Antipsychotic Induced Movement Disorders" - Prakash Masand, MD (Duke-NUS)
4:00 – 5:00 PM: “Pharmacotherapy of Narcolepsy and Insomnia” - Michael Thorpy, MD (Montefiore Medical Center)
Day 2 - Saturday, September 9
7:30 – 8:30 AM: Breakfast
8:30 – 9:30 AM: “Pharmacotherapy of Bipolar Spectrum Disorders" - Joseph Goldberg, MD (Mt. Sinai)
9:30 – 10:30 AM: “Pharmacotherapy of Treatment Resistant Mood Disorders” - Dan Iosifescu, MD (NYU)
10:30 – 11:30 AM: "Role of Long-Acting Injectables in Psychiatric Illness" - Joseph McEvoy, MD (Georgia Regents University)
11:30 -11:45 AM: Coffee Break
11:45 AM – 12:45 PM: Hot Topics (Six clinically relevant and topical issues for 8 minutes each)
12:45 – 2:00 PM: Lunch
2:00 – 3:00 PM: "Pharmacotherapy of Substance Abuse Disorders in Psychiatric Patients" - Ashwin Patkar, MD (Duke)
3:00 – 4:00 PM: “Pharmacotherapy of ADHD Across the Life Cycle” - Anthony Rostain, MD (University of Pennsylvania)
4:00 – 5:00 PM: "Pharmacotherapy of Anxiety Disorders" - Greg Mattingly, MD (Washington University)
*Note, tentative agenda, subject to change.